1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Journal Article (6438)
  2. Meeting Abstract (5172)
  3. Review (332)
  4. Book Section (310)
  5. Editorial (92)
  6. Research Letter (73)
  7. Guidelines (52)
  8. Correspondence (47)
  9. Conference Paper (38)
  10. Miscellaneous (37)
  11. Book Whole (24)
Groups
  1. Department of Pathology and Laboratory Medicine (12615)
  2. GSK Faculty (4773)
  3. Department of Medicine (4722)
  4. Surgery (3639)
  5. Solid Tumor Oncology Division (3422)
  6. Human Oncology and Pathogenesis Program (3037)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Victor Reuter (1228)
  3. Cristina Antonescu (895)
  4. Michael Berger (765)
  5. William Travis (743)
  6. Jinru Shia (719)

More People

Years
  1. 2025 (307)
  2. 2024 (719)
  3. 2023 (766)
  4. 2022 (841)
  5. 2021 (677)
  6. 2020 (787)

More Years

Publications
  1. Laboratory Investigation (1448)
  2. Modern Pathology (1440)
  3. Journal of Clinical Oncology (863)
  4. American Journal of Surgical Pathology (429)
  5. Cancer Research (426)
  6. Blood (349)

More Publications

Publishers
  1. Nature Publishing Group (1939)
  2. Nature Research (1457)
  3. Elsevier Inc. (1139)
  4. American Society of Clinical Oncology (955)
  5. American Association for Cancer Research (923)
  6. Lippincott Williams & Wilkins (896)

More Publishers

Results (12615)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs)
    Meeting Abstract

    McBride, R. B.; Patel, V. G.; Lorduy, A. C.; Castillo-Martin, M.; Cha, E. K.; Berger, M. F.; Wang, L.; Oh, W. K.; Zhu, J.; Cordon-Cardo, C.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Comprehensive molecular profiling and analysis of mutual exclusivity of genetic aberrations (MEGA) of intra- and extrahepatic cholangiocarcinomas (IHC and EHC) evaluation of prognostic features and potential targets for intervention
    Meeting Abstract

    Lowery, M. A.; Ptashkin, R.; Jordan, E.; Berger, M. F.; Zehir, A.; Kemeny, N. E.; O'Reilly, E. M.; Jarnagin, W. R.; Harding, J. J.; DeMatteo, R. P.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Identifying HER2 mutation, amplification, and HER2 protein overexpression as therapeutic targets in lung cancers
    Meeting Abstract

    Li, B. T.; Zheng, T.; Ni, A.; Hellmann, M. D.; Jordan, E.; Barron, D.; Smyth, L. M.; Solit, D. B.; Zehir, A.; Ross, D. S.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Genomic and metabolic characterization of succinate dehydrogenase B deficient renal cell carcinoma
    Meeting Abstract

    Lee, C. H.; Wei, E.; Lee, W.; Chen, Y.; Mano, R.; Hakimi, A. A.; Dong, Y.; Redzematovic, A.; Cross, J. R.; Tickoo, S.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Genomic profiling of pancreas ductal adenocarcinoma (PDA), actionability, and correlation with clinical phenotype
    Meeting Abstract

    Jordan, E.; Lowery, M. A.; Ptashkin, R.; Zehir, A.; Berger, M. F.; Maynard, H.; Glassman, D. C.; Covington, C. M.; Schultz, N.; Abou-Alfa, G. K.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Next generation sequencing (NGS) in lung adenocarcinoma (LA) as a guide to treatment selection
    Meeting Abstract

    Jordan, E.; Barron, D.; Schultz, N.; Chakravarty, D.; Kris, M. G.; Rudin, C. M.; Li, B. T.; Yu, H. A.; Drilon, A. E.; Rusch, V. W.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Emergence of RTK/RAS/PI3K pathway alterations in trastuzumab-refractory HER2-positive esophagogastric (EG) tumors
    Meeting Abstract

    Janjigian, Y. Y.; Sanchez-Vega, F.; Tuvy, Y.; Bouvier, N.; Riches, J. C.; Margolis, M.; Millang, B. M.; Scott, S. N.; Kundra, R.; Castel, P.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC)
    Meeting Abstract

    Iyer, G.; Balar, A. V.; Milowsky, M. I.; Huang, W. C.; Woods, M.; Donat, S. M.; Herr, H. W.; Dalbagni, G.; Bochner, B. H.; Ostrovnaya, I.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase II study of regorafenib in progressive, recurrent/metastatic adenoid cystic carcinoma
    Meeting Abstract

    Ho, A. L.; Sherman, E. J.; Baxi, S. S.; Haque, S.; Ni, A.; Antonescu, C. R.; Katabi, N.; Morris, L. G.; Chan, T. A. T.; Pfister, D. G.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Outcomes of systemic therapy for patients with metastatic undifferentiated pleomorphic sarcoma (UPS)
    Meeting Abstract

    Adrianzen Herrera, D. A.; Kuk, D.; Keohan, M. L.; Dickson, M. A.; D'Angelo, S. P.; Chi, P.; Agaram, N. P.; Antonescu, C. R.; Hameed, M.; Tap, W. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save